--- title: "Perrigo Earnings Call Balances Pressure and Progress" type: "News" locale: "en" url: "https://longbridge.com/en/news/296043897.md" description: "Perrigo's Q2 earnings call highlighted a cautious outlook, balancing operational progress with financial headwinds. The company achieved market share gains in the U.S. and Europe, improved service levels, and saw strong growth in Infant Formula. However, top-line sales declined due to retailer destocking and category softness, while margins compressed. Perrigo continues portfolio simplification and debt reduction, aiming for $80–$100 million in savings by 2027, despite an expected EPS headwind in 2026." datetime: "2026-08-17T00:28:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296043897.md) - [en](https://longbridge.com/en/news/296043897.md) - [zh-HK](https://longbridge.com/zh-HK/news/296043897.md) generator: "portal-rs" --- # Perrigo Earnings Call Balances Pressure and Progress Perrigo Company ((PRGO)) has held its Q2 earnings call. Read on for the main highlights of the call. ### Summer Sale - Claim 70% Off TipRanks - Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions - Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Perrigo’s latest earnings call struck a cautiously upbeat tone as management highlighted operational wins and strategic progress against a backdrop of weaker sales and compressed margins. Executives pointed to market share gains, a sharp turnaround in Infant Formula and ongoing cost savings, but also acknowledged retailer destocking, softer categories and a meaningful EPS headwind in 2026. ## Market Share Gains in U.S. and Europe Perrigo continued to outgrow its categories on both sides of the Atlantic, signaling sustained competitive momentum despite weaker consumer demand. U.S. store brand OTC volumes rose 1.5% while categories fell 1.1%, and key European brands gained share in a shrinking market, with an extra boost reported in early Q3. ## Service Level and Operational Execution Improvement The company underscored significant improvements in service levels as a key driver of stronger retailer partnerships and shelf presence. U.S. service levels climbed 1,600 basis points to 91% and international reached 95%, helping support the market share gains even as some retailers trimmed inventories. ## Infant Formula Turnaround Infant Formula emerged as a standout recovery story, delivering 23% year‑over‑year net sales growth and a roughly $60 million improvement in operating income. Management credited capacity rationalization, efficiency gains and lower scrap and obsolescence, positioning the business as a renewed profit engine within the portfolio. ## Portfolio Simplification and Debt Reduction Perrigo continued to streamline its portfolio while using proceeds to de‑risk the balance sheet, even though divestitures weighed on reported sales. Since 2024, about $600 million in upfront proceeds have been raised, including $359 million from the Dermacosmetics sale in Q2, most of which went to paying down revolving credit borrowings. ## Operational Enhancement Program and One‑time Benefits An operational enhancement program remains on track to deliver $80–$100 million in savings by 2027, providing a structural tailwind to margins over time. Q2 results were also helped by temporary items, including a CEO transition benefit and a tariff recovery, which lifted earnings above what underlying trends alone would have delivered. ## Innovation and Growth Building Blocks Management emphasized its expanded innovation pipeline as a key lever for future growth, noting that its value has more than tripled since 2024. Over half of projects now use shared platforms, allowing more scalable launches across store brand and branded products, with current momentum examples including Opill and Compeed. ## Liquidity and Cash Flow The company’s cash generation remained solid, giving it flexibility as it balances investment with deleveraging. Q2 operating cash flow reached $83 million, cash and equivalents were $400 million, capital spending was held to $14 million and shareholders received $40 million in dividends. ## Top‑line Declines Despite share gains, Perrigo’s top line declined as both category softness and portfolio pruning took their toll. Core net sales fell 3.1% and Core organic net sales 3.5%, while all‑in net sales declined 3.2%, reflecting weaker volumes and the impact of the Dermacosmetics divestiture. ## Retailer Destocking and Category Softness Retailer destocking, particularly in Europe, created an additional drag on reported performance and obscured some underlying momentum. Inventory reductions accounted for roughly a 1.8% sales headwind, with another 1.2% tied to softer cough, cold, pain and allergy demand and a tougher comparison to last year’s strong season. ## Margin Compression Margins came under pressure as mix, under‑absorption and category dynamics offset some of the operational improvements. Core adjusted gross margin slid 250 basis points to 37% and all‑in gross margin mirrored that drop, while Core adjusted operating margin fell to 13% and all‑in operating margin to 12.2%. ## Earnings Declines and Under‑absorption Headwind Earnings declined in step with weaker sales and lower margins, and management signaled further pressure ahead from planned under‑absorption. Core adjusted EPS slipped to $0.46 and all‑in adjusted EPS to $0.50, and the company expects about a $0.60 all‑in EPS headwind in 2026, a portion of which has already flowed through results. ## Specialty Care and Skin Health Weakness Specialty Care remained a soft spot within the broader portfolio, dragging on segment profitability despite strength elsewhere. Net sales declined modestly, while operating income dropped about 28% year‑over‑year, weighed down by weaker Skin Health trends, lower store‑brand Minoxidil contract manufacturing and tough comparisons. ## Ongoing Leverage and Debt Load The balance sheet still carries a notable debt burden, even after the latest round of repayments from asset sales. Total debt stood at roughly $3.3 billion at quarter end, and management reiterated leverage reduction as a key priority as it uses divestiture proceeds and cash flow to gradually strengthen its financial position. ## Impact of Divestiture on Reported Sales Management reminded investors that the Dermacosmetics divestiture, while strategically positive, has mechanically reduced reported net sales in the near term. The transaction highlights Perrigo’s shift toward a more focused self‑care and Infant Formula mix, even as it temporarily lowers the top line and complicates year‑over‑year comparisons. ## Forward‑looking Guidance and Outlook Perrigo reaffirmed its full‑year 2026 outlook for sales, margins and EPS, signaling confidence that the second half will show better trends. Management expects improvement from innovation launches, broader distribution and demand‑generation, plus easing category comparisons and operational actions, while also counting on cost savings and lower interest expense to help offset planned under‑absorption. Perrigo’s earnings call painted a picture of a business in transition, trading short‑term revenue and margin pressure for longer‑term stability and growth. For investors, the key watchpoints will be execution on innovation, continued strength in Infant Formula, progress on deleveraging and how effectively management manages the EPS drag from under‑absorption over the next two years. ### Related Stocks - [PRGO.US](https://longbridge.com/en/quote/PRGO.US.md) ## Related News & Research - [Perrigo’s Q2 Return To Profit Amid Lower Sales Might Change The Case For Investing In PRGO](https://longbridge.com/en/news/296008507.md) - [Perrigo Company Reaffirms Full-Year 2026 Outlook](https://longbridge.com/en/news/294973320.md) - [Abbott settles appeal over $495 million infant formula verdict](https://longbridge.com/en/news/296386129.md) - [Yielding 5.8%, is Verizon stock a buying opportunity?](https://longbridge.com/en/news/296305106.md) - [PRGO: Structural improvements and a diversified portfolio drive growth in a resilient healthcare market](https://longbridge.com/en/news/295680501.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**